IP Library › Granted Patent US 12,516,349
Granted Patent B2
US 12,516,349 · App. 17/425,309 · Granted Jan 6, 2026

Methods and systems for manufacturing viral vectors

Inventors: Stephen Michael Dicker (Wakefield, MA); Julia Ruth Deuel (Melrose, MA); Vimal H. Vaidya (Schnecksville, PA)
Assignee: Regeneron Pharmaceuticals, Inc.
C12N15/86G01N15/14G01N30/74C12N2740/15043C12N2740/15051
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,516,349
App. No.
17/425,309
Granted
Jan 6, 2026
Kind
B2
Abstract

Disclosed herein are methods and systems for manufacturing viral vectors (e.g., lentiviral vectors) using a static light scattering device in-line with a manufacturing process.

Claims (8)

1 . A method for concentrating viral particles in a viral vector manufacturing process comprising filtering a solution comprising viral particles using tangential flow filtration in-line with a MALS device; wherein the MALS device determines the real-time concentration of the viral particles in solution and automates the filtering of the solution until the real-time concentration is substantially equal to a target concentration of the viral particles in the solution.

2 . The method of claim 1 , further comprising clarifying the viral particles and/or purifying the viral particles.

3 . The method of claim 2 , wherein the MALS device is used in-line with a filtration unit to control purification of the viral particles from impurities based on particle size.

4 . The method of claim 3 , wherein the filtration unit is a normal flow filtration unit.

5 . The method of claim 3 , wherein a second filtration unit is used in-line with the MALS device, and wherein the second filtration unit is an ultrafiltration unit.

6 . The method of claim 2 , wherein a first MALS device is used to control concentration of the viral particles and a second MALS device is used to control purification of the viral particles.

7 . The method of claim 2 , wherein the viral particles are selected from the group consisting of adeno-associated virus (AAV), retrovirus, herpes simplex virus, adenovirus, and vaccinia virus particles.

8 . The method of claim 2 , wherein the viral particles are lentiviral particles.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 22, 2024
From: 2SEVENTY BIO, INC.
To: REGENERON PHARMACEUTICALS, INC.
Reel/Frame 067180/0130 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 14, 2021
From: BLUEBIRD BIO, INC.
To: 2SEVENTY BIO, INC.
Reel/Frame 057683/0099 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 13, 2021
From: DICKER, STEPHEN MICHAEL; DEUEL, JULIA RUTH; VAIDYA, VIMAL H.
To: BLUEBIRD BIO, INC.
Reel/Frame 057456/0697 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 2, 2021
From: DICKER, STEPHEN MICHAEL; DEUEL, JULIA RUTH; VAIDYA, VIMAL H.
To: BLUEBIRD BIO, INC.
Reel/Frame 057370/0858 →
Continuity (2)
Provisional Application 62795513 · Jan 22, 2019
Related Publication 20220106610A1 · Apr 7, 2022
References Cited (23)
US 6316185B1 · Saifer · 2001 [cited by examiner]
US 20030199100A1 · Wick · 2003 [cited by applicant]
US 20140302158A1 · Cabrera · 2014 [cited by examiner]
US 20160033470A1 · Reed · 2016 [cited by examiner]
US 20180072777A1 · Rutten et al. · 2018 [cited by applicant]
US 20180094280A1 · Kutner et al. · 2018 [cited by applicant]
US 20180119110A1 · Schlegl et al. · 2018 [cited by applicant]
US 20210154231A1 · Li et al. · 2021 [cited by applicant]
EP 2765138A2 · 2014 [cited by applicant]
WO 2019070424A1 · 2019 [cited by applicant]
Buclez, P.-O., et al., 2016, Rapid, scalable, and low-cost purification of recombinant adeno-associated virus produced by baculovirus expression vector system, Mol. Ther. Meth. Clin. Develop. 3:16035, 1-10. [cited by examiner]
Aguilar et al., At-line multi-angle light scattering detector for faster process development in enveloped virus-like particle purification. J Sep Sci. Aug. 2019;42(16):2640-2649. [cited by applicant]
Chen et al., The potential of adoptive transfer of gamma 9 delta 2 T cells to enhance blinatumomab's antitumor activity against B-cell malignancy. Sci Rep. Jun. 11, 2021;11(1):12398, 15 pages. [cited by applicant]
Guo et al., TIM-3 blockade combined with bispecific antibody MT110 enhances the anti-tumor effect of gamma delta T cells. Cancer Immunol Immunother. Dec. 2020;69(12):2571-2587. [cited by applicant]
Hoh et al., The activity of gamma delta T cells against paediatric liver tumour cells and spheroids in cell culture. Liver Int. Jan. 2013;33(1):127-36. [cited by applicant]
Oberg et al., Bispecific antibodies enhance tumor-infiltrating T cell cytotoxicity against autologous HER-2-expressing high-grade ovarian tumors. J Leukoc Biol. Jun. 2020; 107(6):1081-1095. [cited by applicant]
Oberg et al., Novel bispecific antibodies increase gamma delta T-cell cytotoxicity against pancreatic cancer cells. Cancer Res. Mar. 1, 2014;74(5):1349-60. [cited by applicant]
Opitz et al., Sulfated membrane adsorbers for economic pseudo-affinity capture of influenza virus particles. Biotechnol Bioeng. Aug. 15, 2009; 103(6):1144-54. [cited by applicant]
Patterson et al., Virus-like nanoreactors: programmed encapsulation of the thermostable CelB glycosidase inside the P22 capsid. Soft Matter. 2012;8(39):10158-10166. [cited by applicant]
Wickramasinghe et al., Tangential flow microfiltration and ultrafiltration for human influenza A virus concentration and purification. Biotechnol Bioeng. Oct. 20, 2005;92(2):199-208. [cited by applicant]
Yazdanifar et al., gamma delta T Cells: The Ideal Tool for Cancer Immunotherapy. Cells. May 24, 2020;9(5):1305, 26 pages. [cited by applicant]
International Search Report and Written Opinion for Application No. PCT/US2020/014668, dated Apr. 14, 2020, 20 pages. [cited by applicant]
International Search Report and Written Opinion for Application No. PCT/US2023/065437, dated Jul. 21, 2023, 11 pages. [cited by applicant]